ATG16L2: A Potential Drug Target and Biomarker (G89849)

Target Name: ATG16L2

NCBI ID: G89849

ATG16L2

ATG16L2: A Potential Drug Target and Biomarker

ATG16L2, also known as APG16-like 2, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its unique structure and function have made it an attractive target for drug development, particularly for the treatment of neurodegenerative diseases.

ATG16L2 is a small non-coding RNA molecule that consists of 16 exons. It is characterized by a stem-loop structure and a conserved tail region that is similar to the TATA-binding protein (TBP). The stem-loop region is the most conserved part of the molecule and is involved in the formation of a protein-protein interaction network.

ATG16L2 has been shown to play a role in various cellular processes, including cell growth, differentiation, and RNA homeostasis. It has also been shown to be involved in the regulation of gene expression and to function as a negative regulator of the translation machinery.

One of the most promising aspects of ATG16L2 is its potential as a drug target. Its unique structure and function have made it an attractive target for small molecule inhibitors. Studies have shown that small molecules can interact with ATG16L2 and prevent it from forming protein-protein interactions, which could lead to the inhibition of its function as a negative regulator of the translation machinery. This would result in the translation of less protein, which could lead to neurodegeneration and the development of neurodegenerative diseases.

In addition to its potential as a drug target, ATG16L2 has also been identified as a potential biomarker for the diagnosis and monitoring of neurodegenerative diseases. Its expression has been shown to be affected by various neurological conditions, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. This suggests that its levels may be a useful biomarker for the diagnosis and monitoring of these conditions.

The identification of ATG16L2 as a potential drug target and biomarker has led to a significant increase in the number of studies focused on its research. Further research is needed to fully understand its function and its potential as a drug.

Protein Name: Autophagy Related 16 Like 2

Functions: May play a role in regulating epithelial homeostasis in an ATG16L1-dependent manner

The "ATG16L2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATG16L2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets